These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10801785)

  • 1. Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation.
    Trumbo TA; Maurer MC
    J Biol Chem; 2000 Jul; 275(27):20627-31. PubMed ID: 10801785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombin hydrolysis of V29F and V34L mutants of factor XIII (28-41) reveals roles of the P(9) and P(4) positions in factor XIII activation.
    Trumbo TA; Maurer MC
    Biochemistry; 2002 Feb; 41(8):2859-68. PubMed ID: 11851434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of introducing fibrinogen Aalpha character into the factor XIII activation peptide segment.
    Jadhav MA; Isetti G; Trumbo TA; Maurer MC
    Biochemistry; 2010 Apr; 49(13):2918-24. PubMed ID: 20218626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. V34I and V34A substitutions within the factor XIII activation peptide segment (28-41) affect interactions with the thrombin active site.
    Trumbo TA; Maurer MC
    Thromb Haemost; 2003 Apr; 89(4):647-53. PubMed ID: 12669118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombin activity is unaltered by N-terminal truncation of factor XIII activation peptides.
    Isetti G; Maurer MC
    Biochemistry; 2004 Apr; 43(14):4150-9. PubMed ID: 15065858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Employing mutants to study thrombin residues responsible for factor XIII activation peptide recognition: a kinetic study.
    Isetti G; Maurer MC
    Biochemistry; 2007 Mar; 46(9):2444-52. PubMed ID: 17286389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probing interactions between the coagulants thrombin, Factor XIII, and fibrin(ogen).
    Maurer MC; Trumbo TA; Isetti G; Turner BT
    Arch Biochem Biophys; 2006 Jan; 445(1):36-45. PubMed ID: 16364233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening cleavage of Factor XIII V34X Activation Peptides by thrombin mutants: A strategy for controlling fibrin architecture.
    Jadhav MA; Goldsberry WN; Zink SE; Lamb KN; Simmons KE; Riposo CM; Anokhin BA; Maurer MC
    Biochim Biophys Acta Proteins Proteom; 2017 Oct; 1865(10):1246-1254. PubMed ID: 28687225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure.
    Ariëns RA; Philippou H; Nagaswami C; Weisel JW; Lane DA; Grant PJ
    Blood; 2000 Aug; 96(3):988-95. PubMed ID: 10910914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probing thrombin's ability to accommodate a V34F substitution within the factor XIII activation peptide segment (28-41).
    Isetti G; Maurer MC
    J Pept Res; 2004 Mar; 63(3):241-52. PubMed ID: 15049836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of gamma A/gamma ' fibrinogen in plasma factor XIII activation.
    Moaddel M; Falls LA; Farrell DH
    J Biol Chem; 2000 Oct; 275(41):32135-40. PubMed ID: 10913112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of Factor XIII V34X activation peptides to control ability to interact with thrombin mutants.
    Jadhav MA; Lucas RC; Goldsberry WN; Maurer MC
    Biochim Biophys Acta; 2011 Dec; 1814(12):1955-63. PubMed ID: 21798378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coagulation factor XIII variants with altered thrombin activation rates.
    Andersen MD; Kjalke M; Bang S; Lautrup-Larsen I; Becker P; Andersen AS; Olsen OH; Stennicke HR
    Biol Chem; 2009 Dec; 390(12):1279-83. PubMed ID: 19804366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling of factor XIII activation peptide (28-41) V34L mutant bound to thrombin.
    Nair DG; Sunilkumar PN; Sadasivan C
    J Biomol Struct Dyn; 2008 Dec; 26(3):387-94. PubMed ID: 18808204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promotion of thrombin-catalyzed activation of factor XIII by fibrinogen.
    Janus TJ; Lewis SD; Lorand L; Shafer JA
    Biochemistry; 1983 Dec; 22(26):6269-72. PubMed ID: 6661434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Val34Leu and Val35Leu polymorphism on the enzyme activity of the coagulation factor XIII-A.
    Lee IH; Chung SI; Lee SY
    Exp Mol Med; 2002 Nov; 34(5):385-90. PubMed ID: 12526104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor XIII A-Subunit V34L Variant Affects Thrombus Cross-Linking in a Murine Model of Thrombosis.
    Duval C; Ali M; Chaudhry WW; Ridger VC; Ariëns RA; Philippou H
    Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):308-16. PubMed ID: 26743168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catalytic competence of human alpha- and gamma-thrombin in the activation of fibrinogen and factor XIII.
    Lewis SD; Lorand L; Fenton JW; Shafer JA
    Biochemistry; 1987 Dec; 26(24):7597-603. PubMed ID: 3427095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the activation of bovine plasma factor XIII. Amino acid sequence of the peptide released by thrombin and the terminal residues of the subunit polypeptides.
    Nakamura S; Iwanaga S; Suzuki T
    J Biochem; 1975 Dec; 78(6):1247-66. PubMed ID: 1225922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of low specificity and cofactor interaction sites on thrombin during factor XIII activation. Competition for cofactor sites on thrombin determines its fate.
    Philippou H; Rance J; Myles T; Hall SW; Ariens RA; Grant PJ; Leung L; Lane DA
    J Biol Chem; 2003 Aug; 278(34):32020-6. PubMed ID: 12794066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.